Management of chemotherapy-associated febrile neutropenia

AUTOR(ES)

Cameron, D

FONTE

Nature Publishing Group

RESUMO

The development of febrile neutropenia during a course of chemotherapy is not only a life-threatening complication, it can also lead to a decision to reduce chemotherapy intensity in subsequent treatment cycles, thus putting patient outcomes at risk. Although there are strategies available for the primary prevention of febrile neutropenia, these are not widely used in the UK management of breast cancer. It is, therefore, paramount to have a well thought out and rigorously implemented care protocol for febrile neutropenia, involving patients, family/carers and health-care professionals in both primary and secondary care, to ensure early detection and effective management.

Documentos Relacionados

• Impact of effective prevention and management of febrile neutropenia
• Use of biomarkers in the management of febrile neutropenia episodes in children with cancer
• Febrile neutropenia studies in Brazil: treatment and cost management based on analyses of cases
• Coronaviruses in children with febrile neutropenia
• Prevention of febrile neutropenia: use of prophylactic antibiotics